Contact Us

Please use the form on the right to contact us. We are always looking for new partners to help us leverage and advance our technology for the discovery of new compounds.


3210 Merryfield row
San Diego, CA 92121





Accelerate your antibiotic discovery research with Bacterial Cytological Profiling (BCP).  BCP uses quantitative cell biology methods to study how different conditions or drugs affect the overall cytological characteristics of microbial cells.  BCP detects disturbances in all essential cellular pathways in a single, rapid test, making it a powerful antibiotic discovery platform.  

At Linnaeus Bioscience Inc., we are using BCP to identify the mode of action (MOA) of new antibiotics, information key to identifying molecules hitting new targets and for advancing these hits through the drug development pipeline.  Linnaeus has developed a high throughput screening BCP (HTP-BCP) platform useful for identifying hits from large chemical or natural product libraries with unparalleled sensitivity.  BCP reports MOA information for 100% of the hits obtained from screening, allowing investigators to immediately focus on the best hits in their collection.  BCP technology is capable of detecting cytological changes that do not impair growth, making it highly sensitive and allowing the discovery of molecules previously missed by other whole cell based screens.  BCP can identify molecules that have multiple MOAs that are traditionally more difficult to characterize but highly desired due to their inherently low rates of resistance.   

BCP works with all types of potential antimicrobial compounds, including small synthetic chemicals, crude natural product extracts, fractionated natural products, peptides, or synthetic molecules that mimic peptides.

BCP technology can also be used to identify compounds that do not kill but alter the cell in critical ways useful for developing new treatments. For example, BCP can sensitively identify compounds that specifically permeabilize the outer membrane of Gram negative bacteria without affecting the inner membrane or cell growth.  Such permeabilization agents sensitize bacteria to many clinically approved compounds and can be used in combination therapy to enhance susceptibility of Gram negative pathogens to many types of conventional antibiotics.